Cancer Stem Cells and Tumor-associated Macrophages As Mates in Tumor Progression: Mechanisms of Crosstalk and Advanced Bioinformatic Tools to Dissect Their Phenotypes and Interaction

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2025 Feb 21

PMID 39981232

Authors

Francesco Verona

Sebastiano Di Bella

Roberto Schirano

Camilla Manfredi

Francesca Angeloro

Giulia Bozzari

Matilde Todaro

Giuseppe Giannini

Giorgio Stassi

Veronica Veschi

Affiliations

Soon will be listed here.

Abstract

Cancer stem cells (CSCs) are a small subset within the tumor mass significantly contributing to cancer progression through dysregulation of various oncogenic pathways, driving tumor growth, chemoresistance and metastasis formation. The aggressive behavior of CSCs is guided by several intracellular signaling pathways such as WNT, NF-kappa-B, NOTCH, Hedgehog, JAK-STAT, PI3K/AKT1/MTOR, TGF/SMAD, PPAR and MAPK kinases, as well as extracellular vesicles such as exosomes, and extracellular signaling molecules such as cytokines, chemokines, pro-angiogenetic and growth factors, which finely regulate CSC phenotype. In this scenario, tumor microenvironment (TME) is a key player in the establishment of a permissive tumor niche, where CSCs engage in intricate communications with diverse immune cells. The "oncogenic" immune cells are mainly represented by B and T lymphocytes, NK cells, and dendritic cells. Among immune cells, macrophages exhibit a more plastic and adaptable phenotype due to their different subpopulations, which are characterized by both immunosuppressive and inflammatory phenotypes. Specifically, tumor-associated macrophages (TAMs) create an immunosuppressive milieu through the production of a plethora of paracrine factors (IL-6, IL-12, TNF-alpha, TGF-beta, CCL1, CCL18) promoting the acquisition by CSCs of a stem-like, invasive and metastatic phenotype. TAMs have demonstrated the ability to communicate with CSCs via direct ligand/receptor (such as CD90/CD11b, LSECtin/BTN3A3, EPHA4/Ephrin) interaction. On the other hand, CSCs exhibited their capacity to influence immune cells, creating a favorable microenvironment for cancer progression. Interestingly, the bidirectional influence of CSCs and TME leads to an epigenetic reprogramming which sustains malignant transformation. Nowadays, the integration of biological and computational data obtained by cutting-edge technologies (single-cell RNA sequencing, spatial transcriptomics, trajectory analysis) has significantly improved the comprehension of the biunivocal multicellular dialogue, providing a comprehensive view of the heterogeneity and dynamics of CSCs, and uncovering alternative mechanisms of immune evasion and therapeutic resistance. Moreover, the combination of biology and computational data will lead to the development of innovative target therapies dampening CSC-TME interaction. Here, we aim to elucidate the most recent insights on CSCs biology and their complex interactions with TME immune cells, specifically TAMs, tracing an exhaustive scenario from the primary tumor to metastasis formation.

References

Cosialls E, El Hage R, Dos Santos L, Gong C, Mehrpour M, Hamai A . Ferroptosis: Cancer Stem Cells Rely on Iron until "to Die for" It. Cells. 2021; 10(11). PMC: 8616391. DOI: 10.3390/cells10112981. View

Wu K, Lin K, Li X, Yuan X, Xu P, Ni P . Redefining Tumor-Associated Macrophage Subpopulations and Functions in the Tumor Microenvironment. Front Immunol. 2020; 11:1731. PMC: 7417513. DOI: 10.3389/fimmu.2020.01731. View

Street K, Risso D, Fletcher R, Das D, Ngai J, Yosef N . Slingshot: cell lineage and pseudotime inference for single-cell transcriptomics. BMC Genomics. 2018; 19(1):477. PMC: 6007078. DOI: 10.1186/s12864-018-4772-0. View

Chen Y, Song Y, Du W, Gong L, Chang H, Zou Z . Tumor-associated macrophages: an accomplice in solid tumor progression. J Biomed Sci. 2019; 26(1):78. PMC: 6800990. DOI: 10.1186/s12929-019-0568-z. View

Zhou D, Qin J, Huang J, Wang F, Xu G, Lv Y . Zoledronic acid inhibits infiltration of tumor-associated macrophages and angiogenesis following transcatheter arterial chemoembolization in rat hepatocellular carcinoma models. Oncol Lett. 2017; 14(4):4078-4084. PMC: 5592878. DOI: 10.3892/ol.2017.6717. View

Naing A, Khalil D, Rosen O, Camidge D, Lillie T, Ji R . First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironments. J Immunother Cancer. 2024; 12(10). PMC: 11481156. DOI: 10.1136/jitc-2024-010016. View

Lo Iacono M, Gaggianesi M, Bianca P, Brancato O, Muratore G, Modica C . Destroying the Shield of Cancer Stem Cells: Natural Compounds as Promising Players in Cancer Therapy. J Clin Med. 2022; 11(23). PMC: 9737492. DOI: 10.3390/jcm11236996. View

Clara J, Monge C, Yang Y, Takebe N . Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update. Nat Rev Clin Oncol. 2019; 17(4):204-232. DOI: 10.1038/s41571-019-0293-2. View

Fan G, Xie T, Li L, Tang L, Han X, Shi Y . Single-cell and spatial analyses revealed the co-location of cancer stem cells and SPP1+ macrophage in hypoxic region that determines the poor prognosis in hepatocellular carcinoma. NPJ Precis Oncol. 2024; 8(1):75. PMC: 10960828. DOI: 10.1038/s41698-024-00564-3. View

10.

Su P, Li O, Ke K, Jiang Z, Wu J, Wang Y . Targeting tumor‑associated macrophages: Critical players in tumor progression and therapeutic strategies (Review). Int J Oncol. 2024; 64(6). PMC: 11087038. DOI: 10.3892/ijo.2024.5648. View

11.

Lendeckel U, Wolke C . Redox-Regulation in Cancer Stem Cells. Biomedicines. 2022; 10(10). PMC: 9598867. DOI: 10.3390/biomedicines10102413. View

12.

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View

13.

Husain K, Coppola D, Yang C, Malafa M . Farnesyl dimethyl chromanol targets colon cancer stem cells and prevents colorectal cancer metastasis. Sci Rep. 2021; 11(1):2185. PMC: 7838198. DOI: 10.1038/s41598-020-80911-z. View

14.

Li D, Ji H, Niu X, Yin L, Wang Y, Gu Y . Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer. Cancer Sci. 2019; 111(1):47-58. PMC: 6942430. DOI: 10.1111/cas.14230. View

15.

Lee J, Lee K, Kim D, Heo D . Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol. 2004; 172(12):7335-40. DOI: 10.4049/jimmunol.172.12.7335. View

16.

Oskarsson T, Batlle E, Massague J . Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell. 2014; 14(3):306-21. PMC: 3998185. DOI: 10.1016/j.stem.2014.02.002. View

17.

Raggi C, Mousa H, Correnti M, Sica A, Invernizzi P . Cancer stem cells and tumor-associated macrophages: a roadmap for multitargeting strategies. Oncogene. 2015; 35(6):671-82. DOI: 10.1038/onc.2015.132. View

18.

Ke Y, Wu C, Zeng Y, Chen M, Li Y, Xie C . Radiosensitization of Clioquinol Combined with Zinc in the Nasopharyngeal Cancer Stem-like Cells by Inhibiting Autophagy in Vitro and in . Int J Biol Sci. 2020; 16(5):777-789. PMC: 7019136. DOI: 10.7150/ijbs.40305. View

19.

Wang H, Yang M, Lin L, Ren H, Lin C, Lin S . HepG2 cells acquire stem cell-like characteristics after immune cell stimulation. Cell Oncol (Dordr). 2015; 39(1):35-45. DOI: 10.1007/s13402-015-0249-1. View

20.

McWhirter S, Jefferies C . Nucleic Acid Sensors as Therapeutic Targets for Human Disease. Immunity. 2020; 53(1):78-97. DOI: 10.1016/j.immuni.2020.04.004. View